白蛋白结合型紫杉醇二线及以上治疗晚期非小细胞肺癌的单臂、单中心探索性临床研究

doi:10.12092/j.issn.1009-2501.2019.11.011

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (11): 1281-1286.doi: 10.12092/j.issn.1009-2501.2019.11.011

白蛋白结合型紫杉醇二线及以上治疗晚期非小细胞肺癌的单臂、单中心探索性临床研究

杨科¹，李峻岭²，杜斌¹，田中秋¹，景秀娟¹

¹北京桓兴肿瘤医院肿瘤科，北京100065；²中国医学科学院肿瘤医院肿瘤科，北京100021

收稿日期:2019-04-15 修回日期:2019-10-12 出版日期:2019-11-26 发布日期:2019-12-02
通讯作者: 李峻岭，男，博士研究生，主任医师，研究方向：肺癌内科治疗研究。 Tel: 13801178891 E-mail：lijunling@cicams.ac.cn
作者简介:杨科，男，在读硕士，主治医师，研究方向：中晚期肿瘤内科治疗研究。 Tel: 13522575737 E-mail：13522575737@163.com
基金资助:
北京医学奖励基金（2017-015-ZZ）

Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer

YANG Ke¹, LI Junling², DU Bin¹, TIAN Zhongqiu¹, JING Xiujuan¹

¹ Department of Medical Oncology, Cancer Hospital of HuanXing ChaoYang District Beijing, Beijing 100065, China; ²Department of Medical Oncology, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing 100021, China

Received:2019-04-15 Revised:2019-10-12 Online:2019-11-26 Published:2019-12-02

摘要/Abstract

摘要：

目的:探讨白蛋白结合型紫杉醇二线及以上治疗晚期非小细胞肺癌的疗效及安全性。方法:选取2012年10月到2015年12月入组前接受过至少一线治疗方案失败的晚期非小细胞肺癌患者63例，给予白蛋白结合型紫杉醇130 mg/m2，第1天和第8天静脉滴注治疗，21 d为一个周期。每2个周期进行疗效评价，用CTCAE4.03版本的标准评价每个周期出现的不良反应。患者疾病进展后通过电话随访获取患者的预后数据。结果:纳入研究的63例患者均可评价疗效，其中接受治疗后疗效达到完全缓解（CR）0例，部分缓解（PR）15例，疾病稳定（SD）21例，疾病进展（PD）27例。该研究的客观缓解率（ORR）为23.81%，疾病控制率（DCR）为57.14%。经过随访预后，63例患者的中位无进展生存期（mPFS）为3.9个月（95%CI：3.1-5.2），中位总生存期（mOS）为9.3个月（95%CI：7.8-10.4）。安全性方面，主要的2级以上不良反应为中性粒细胞减少，血小板减少，脱发和外周神经毒性，总体不良反应可耐受。结论:白蛋白结合型紫杉醇二线及以上治疗晚期非小细胞肺癌患者具有不错的疗效，不良事件可控，有望成为晚期非小细胞肺癌二线治疗标准。

关键词: 非小细胞肺癌, 白蛋白结合型紫杉醇, 疗效, 安全性

Abstract:

AIM: To explore the efficacy and safety of second and more line treatment with albumin-bound paclitaxel for advanced non-small cell lung cancer. METHODS: From Oct 2012 to Dec 2015, a total of 63 patients with advanced non-small cell lung cancer who had failed previously first-line and more line treatment were enrolled in this study. The patients were treated with 130 mg/m2 intravenous infusion albumin-binding paclitaxel on day 1 and day 8, 21 days one cycle. The efficacy was evaluated every 2 cycles, and adverse reactions were recorded using the CTCAE4.03 version. Patients were followed up by telephone to obtain prognostic data after disease progression. RESULTS:All of the 63 patients were available for efficacy evaluation, among them, complete remission (CR) 0 case, partial remission (PR) 15 case, stable disease (SD) 21 case, progression disease (PD) 27 case. Objective response rate (ORR) was 23.81%, disease control rate (DCR) was 57.14%, median Progression-free survival (PFS) of the 63 patients was 3.9 months (95%CI: 3.1-5.2), median Overall survival (OS) was 9.3 months (95%CI: 7.8-10.4). In terms of safety analysis, the major grade 2 and above adverse reactions were neutropenia, thrombocytopenia, alopecia and peripheral neurotoxicity, and the overall adverse reactions were tolerable. CONCLUSION:The second and more line treatment with albumin-bound paclitaxel in patients with advanced non-small cell lung cancer has superior efficacy and controllable adverse events, which is expected to become the second-line treatment standard regimens for advanced NSCLC.

Key words: non-small cell lung cancer, albumin bound paclitaxel, efficacy, safety

中图分类号:

杨科，李峻岭，杜斌，田中秋，景秀娟. 白蛋白结合型紫杉醇二线及以上治疗晚期非小细胞肺癌的单臂、单中心探索性临床研究[J]. 中国临床药理学与治疗学, 2019, 24(11): 1281-1286.

YANG Ke, LI Junling, DU Bin, TIAN Zhongqiu, JING Xiujuan. Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1281-1286.

参考文献

［1］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin,2016,66(2):115-32.
［2］王海霞, 刘兴安, 侯继院, 等. KDR基因遗传变异对贝伐珠单抗一线治疗晚期非小细胞肺癌患者临床疗效的影响［J］. 中国临床药理学与治疗学, 2018, 23(7): 802-808.
［3］Protopapa M, Kouloulias V, Nikoloudi S, et al. From whole-brain radiotherapy to immunotherapy: A multidisciplinary approach for patients with brain metastases from NSCLC［J］. J Oncol, 2019, 2019: 3267409.
［4］Perdrizet K, Leighl NB.The role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer［J］. Curr Treat Options Oncol, 2019, 20(3): 21.
［5］Prabhash K.Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line-Indian consensus statement update［J］. South Asian J Cancer, 2019, 8(1): 1-17.
［6］Heeke S, Hofman P.Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not［J］? Transl Lung Cancer Res, 2018, 7(6): 631-638.
［7］Nakashima K, Akamatsu H, Murakami H, et al. Carboplatin plus nab-paclitaxel in performance status 2 patients with advanced non-small-cell lung cancer［J］. Anticancer Res, 2019, 39(3): 1463-1468.
［8］Murphy C, Muscat A, Ashley D, et al. Tailored NEOadjuvant epirubicin, cyclophosphamide and nanoparticle albumin-bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response［J］. PLoS One, 2019, 14(2): e0210891.
［9］Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial［J］. J Clin Oncol, 2012, 30(17): 2055-2062.
［10］Holleman MS, van Tinteren H, Groen HJ, et al. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis［J］. Onco Targets Ther, 2019, 12: 1413-1421.
［11］Patel JD, Paz-Ares L, Zinner RG, et al. Pemetrexed continuation maintenance phase 3 trials in nonsquamous, non-small-cell lung cancer: Focus on 2-year overall survival and continuum of care［J］. Clin Lung Cancer, 2018, 19(6): e823-e830.
［12］Lazzari C, Karachaliou N, Gregorc V, et al. Second-line therapy of squamous non-small cell lung cancer: an evolving landscape［J］. Expert Rev Respir Med, 2017, 11(6): 469-479.
［13］Corrales L, Nogueira A, Passiglia F, et al. Second-line treatment of non-small cell lung cancer: Clinical, pathological, and molecular aspects of nintedanib［J］. Front Med (Lausanne), 2017, 4: 13.
［14］Jean F, Tomasini P, Barlesi F.Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy［J］. Ther Adv Med Oncol, 2017, 9(12): 769-779.
［15］Naganuma M, Tahara K, Hasegawa S, et al. Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System［J］. SAGE Open Med, 2019, 7: 2050312119836011.
［16］Cortinovis D, Gregorc V, Migliorino MR, et al. New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group［J］. Crit Rev Oncol Hematol, 2017, 109: 35-41.
［17］Sugawara S, Nakagawa K, Yamamoto N, et al. Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC［J］. Int J Clin Oncol, 2019, 24(5):485-493.
［18］Segal NH, Ou SI, Balmanoukian A, et al. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort［J］. Eur J Cancer, 2019, 109: 154-161.
［19］von Pawel J, Bordoni R, Satouchi M, et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study［J］. Eur J Cancer, 2019, 107: 124-132.
［20］Tan H, Hu J, Liu S.Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis［J］. Artif Cells Nanomed Biotechnol, 2019, 47(1): 268-277.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[3]	刘敏, 孔祥, 章叶, 顾逸飞, 项雪梅, 黄凯. 经口吸入制剂在中国健康受试者生物等效性试验中的安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(10): 1131-1138.
[4]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[5]	张可心, 贾文静, 崔佳文, 敖路遥, 周芳, 王广基, 刘嘉莉. 第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1016-1030.
[6]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[7]	晏玉奎, 胡建琴, 张冰. 新型和传统抗癫痫药物治疗新诊断部分性癫痫的临床研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 793-799.
[8]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[9]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[10]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[11]	裴清华, 孙建立. 奥希替尼获得性耐药的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 105-112.
[12]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[13]	魏为添, 陈晟, 汪亮, 曾剑. 灯盏花素对非小细胞肺癌A549细胞的促凋亡作用[J]. 中国临床药理学与治疗学, 2020, 25(6): 618-624.
[14]	赵倩，杨广，曹莉华，于陈宝. CNR1基因遗传变异对利拉鲁肽治疗早期2型糖尿病患者临床疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(2): 182-188.
[15]	潘露萍，石武杰，沈志鹏. 依托泊苷联合卡铂用于复发性髓母细胞瘤患儿的疗效与安全性[J]. 中国临床药理学与治疗学, 2020, 25(2): 189-195.

白蛋白结合型紫杉醇二线及以上治疗晚期非小细胞肺癌的单臂、单中心探索性临床研究

Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价